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Abstract: Vitamin D and omega 3 fatty acid (ω-3) co-supplementation potentially improves type 1
diabetes (T1D) by attenuating autoimmunity and counteracting inflammation. This cohort study,
preliminary to a randomized control trial (RCT), is aimed at evaluating, in a series of T1D children
assuming Mediterranean diet and an intake of cholecalciferol of 1000U/day from T1D onset, ifω-3
co-supplementation preserves the residual endogen insulin secretion (REIS). Therefore, the cohort
of 22 “new onsets” of 2017 received ω-3 (eicosapentenoic acid (EPA) plus docosahexaenoic acid
(DHA), 60 mg/kg/day), and were compared retrospectively vs. the 37 “previous onsets” without
ω-3 supplementation. Glicosilated hemoglobin (HbA1c%), the daily insulin demand (IU/Kg/day)
and IDAA1c, a composite index (calculated as IU/Kg/day × 4 + HbA1c%), as surrogates of REIS,
were evaluated at recruitment (T0) and 12 months later (T12). In the ω-3 supplemented group,
dietary intakes were evaluated at T0 and T12. As an outcome, a decreased insulin demand (p < 0.01),
particularly as pre-meal boluses (p< 0.01), and IDAA1c (p< 0.05), were found in theω-3 supplemented
group, while HbA1c% was not significantly different. Diet analysis in the ω-3 supplemented group,
at T12 vs. T0, highlighted that the intake of arachidonic acid (AA) decreased (p < 0.01). At T0, the AA
intake was inversely correlated with HbA1c% (p < 0.05; r;. 0.411). In conclusion, the results suggest
that vitamin D plus ω-3 co-supplementation as well as AA reduction in the Mediterranean diet
display benefits for T1D children at onset and deserve further investigation.
Keywords: cholecalciferol; omega3; EPA; DHA; arachidonic acid; AA/EPA ratio; type 1 diabetes;
remission period; honeymoon period
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1. Introduction
Nutraceutic is a neologism made up of the words “nutrition” and “pharmaceutical” which was
coined in 1989 by Stephen de Felice to label the science that focuses on nutritional principles contained
in foods and their beneficial effects on health. This discipline has its roots in the not-so-recent past, but
it has taken on scientific value over the last fifty years. However, it faces inherent difficulties in the
assessment of clinical outcomes for a specific nutrient outside of the whole nutrition [1], which would
be relevant for management of specific diseases. Specific nutrients, such as vitamin D and omega-3
polyunsaturated fatty acids (ω-3), are of concern in type 1 diabetes (T1D), a chronic autoimmune
disease caused by progressive selective destruction of pancreatic β-cells producing insulin, starting
in infancy with the appearance of specific autoantibodies, and with clinical outbreak during the
pediatric age range in 90% of cases. Hyperglycemia is a characteristic sign of the disease and it
requires a precise administration of insulin throughout life in order to restore metabolic control,
but it does not abolish disabling complications over time. T1D entails a great deal of individual, familial,
and social commitment. The rise in incidences of T1D in most developed countries, and its shift towards
younger ages of life, implies that a genetic predisposition must be associated with environmental
factors, including nutrients or other potentially reversible causative agents.
In 2003, Lars C. Stene found a low occurrence of T1D in the coastal areas of Norway with greater
availability of fish, compared to areas in the hinterland [2]. This finding suggested a role of ω-3
and vitamin D as possible environmental determinants of the disease. The prevention capability
of 2000 IU of vitamin D consumed daily over the first year of the patient’s life was reported by
Elina Hyppönen et al. in 2001 [3]. Surprisingly, very few of such innovative studies have become of
clinical utility in the prevention or treatment of T1D, except for a consensus on correcting vitamin D
deficiency [4]. Recently in TEDDY, a large network cohort study, vitamin D orω-3 supplementation
during pregnancy did not confer any effect in the development of islet autoantibodies [5]. Conversely,
in the first years of overt disease, vitamin D andω-3 supplementation have been found to play a clinical
role, as shown by SEARCH, two large prospective nutritional studies, reporting that the amount ofω-3
in the diet correlates inversely with glycosylated hemoglobin (HbA1c%) and positively with persistent
fasting C-peptide (FCP) [6,7].
A possible therapeutic role of vitamin D in T1D might be mediated by its regulatory activity on
the immune system and the autoimmune response through vitamin D receptors expressed on both
immune cells and pancreatic β-cells. The first clinical evidence of this in T1D was given by Treiber et al.,
with the administration of high doses of cholecalciferol (70 IU/kg/day) in a randomized controlled
trial on children with a recent onset of the disease, showing a capacity to restore immunosuppressive
Treg cells and potentially counteract the elective autoimmune damage to pancreatic β-cells [8]. In this
study, the supplementation with vitamin D did not display significant improvement on stimulated
C-peptide (SCP). Recently, in a study of Iranian children at the onset of overt T1D, Habibian et al.
provided evidence of vitamin D as an environmental factor decreasing the fall of C-peptide in children
with recent T1D [9].
The ability of ω-3 to counteract the pathogenic pathways of T1D has been highlighted in two
studies showing that its nutritional intake may reduce blood glucose levels [10] and limit β-cells
apoptosis mediated by glucolipotoxicity [11]. Specifically, diet supplementation withω-3 was found
to lead to reduction of postprandial glycemia and improvement of glycemic variability, mediated
by the inhibition of neoglucogenesis [10], and counteracting β-cell apoptosis through activation of
the Eovl2/docosahexaenoic acid(DHA) enzyme axis [11]. These reports suggest both an immunologic
and metabolic role for ω-3, limiting the post-prandial blood glucose increase, and protecting β-cell
apoptosis induced by glucolipotoxicity. The role of ω-3 and omega-6 polyunsaturated fatty acids
(ω-6) in the regulation of autoimmunity in NOD mice is detailed in a study byXinum Bi et al. [12].
In this work, eicosapentenoic acid (EPA) and DHA reduced the imbalance of Th1/Th2 cells and
the proportion of Th17 cells, and increased Treg. In contrast, the ω-6 arachidonic acid (AA) intake
increased the number of Th17, without significant difference in the count of Treg cells. In the same
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direction, ω-3 supplementation decreased levels of IFN-Υ, IL-17, IL-6, and TNF-α, supporting its
anti-inflammatory ability.
The ideal point in time for testing a possible role of vitamin D andω-3 should be at clinical onset
of T1D when, after the start of insulin therapy and the achievement of stable metabolic compensation,
about 80% of children and adolescents experience a partial remission, reducing insulin demands to
maintain euglycemia. Afterwards, a resumption of the autoimmune process determines a progressive
growth of insulin requirements and brings the so-called “honeymoon phase” of T1D [13] to an end.
Sustaining the recovery of endogen insulin secretion (REIS) should be the ultimate goal of T1D therapy
in order to reduce severe hypoglycemia and avoid its long-term complications [14].
Given that insulin therapy is the first factor conditioning the restoration of the critical mass of
β-cells during the honeymoon phase through stabilization of blood glucose, to date there is limited
experience in the effect of combined supplementations with vitamin D andω-3 within the first year
of overt disease in children. Since anecdotal cases have suggested that this co-supplementation may
prolong REIS [15–17], we looked at the introduction, in a series of T1D children already assuming
Mediterranean diet and supplementation of 1000 IU of cholecalciferol from onset, of an additionalω-3
supplement starting from the first semester of overt disease and evaluate outcomes as a pilot study
before further randomized controlled intervention trials (RCT).
2. Materials and Methods
Intervention group: Starting in January 2017 we prospectively studied 26 new consecutive T1D
onsets referred to the pediatric diabetes service of the University Hospital of Novara (AOU-Novara).
Everyone received training on the Mediterranean diet, a cholecalciferol supplementation of 1000 IU/day,
and within the first semester of overt disease, also was entered to ω-3 supplement of ultra-refined fish
oil, equivalent to 60 mg/kg/day of eicosapentenoic acid (EPA) and docosahexaenoic acid (DHA).
Retrospective controls: All patients with T1D onset in 2014–2016 were admitted to the study as
controls, after having received their parents’ written consent. One patient (n = 38) was excluded
since he was the anecdotic case who received ω-3 supplementation before this study. Data were
structured in a database. The patients had been introduced to the Mediterranean diet (as reported
in the Supplementary Materials S1) and 1000 UI/day cholecalciferol supplementation since the first
month of clinical disease, without aω-3 supplement.
Inclusion and exclusion criteria: Patients with renal cysts or affected by sarcoidosis, histoplasmosis,
hyperparathyroidism, lymphoma, and tuberculosis were excluded. T1D patients with thyroiditis
and celiac disease following a gluten-free diet and who were tissue transglutaminase autoantibody
(tTGA) negative were not excluded. Patients treated with drugs that could affect immunity or glucose
metabolism, including corticosteroids, ciclosporin, and tacrolimus, were excluded.
Recruitment for the study took place from 1 January 2017 to 31 December 2018. The intervention
lasted one year for each case. This study was approved by the ethics committee of AOU Novara, and all
patients’ parents signed the informed consent form. This trial was registered at the ClinicalTrials.gov
website (identifier: NCT03911843).
Diagnosis of T1D was performed according to the American Diabetes Association criteria [18].
Micro or macro vascular complications were defined according to the ISPAD criteria [19]. Children
were evaluated using Italian growth charts [20]. At the onset of the disease, data on the presence of
diabetic ketoacidosis, HbA1c%, insulin requirements, 25(OH)D levels, thyroid function, antibody
titles of GADA, IAA, and IA-2, antibody patterns of celiac disease, and lipid profiles were collected.
Evidence of ketoacidosis was assessed according to the ISPAD criteria [19], and severe DKA was
considered if pH ≤7.1. The vitamin D status, as 25(OH)D levels, sufficiency, deficiency or insufficiency,
were defined according to the Endocrine Society criteria, graded as sufficiency >30 ng/mL(>75 nmol/l),
insufficiency 21–29 ng/mL(52.5–72.5 nmol/l), and deficiency ≤20 ng/mL(≤50 nmol/l) [21,22]. The annual
screening (blood count, lipid profile, urine test, thyroid function, and aPTT coagulation tests) was
performed and evaluated at recruitment(T0) and twelve months later(T12). Blood glucose meters
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(Conturnext USB® Ascensia Diabetes Care) were supplied to the patients enrolled to standardize
blood glucose measurements, and their data were downloaded with dedicated software (Glucofacts®
Ascensia Diabetes Care, FreeStyleLibreLink®, Medtronic CareLink Pro®, Accu-ChekChekSmartPix®,
Diasend® or Dexcom Clarity®). Clinical data, insulin demand, and laboratory analysis results were
entered in a structured database.
2.1. Supplementations
Supplementation of ω-3 was considered the intervention (T0). The preparation administered
was a highly purified fish oil used in order to avoid pollutants, containing a mixture of omega 3
long chain fatty acids (ω-3 LCFA) standardized for contents of eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA), in capsules or in liquid form (Ener Zone Omega 3 RX® Equipe Enervit).
A liquid preparation was used in the case of difficulties in swallowing capsules or concomitant celiac
disease because it is certified as gluten-free. The preparations contained antioxidants to preserve
ω-3 LCFA, tocopherol (1 mg in 1 g of ω-3 LCFA), palmitate, and rosemary extract. EPA and DHA
at 60 mg/kg/day were administered for 12 months. The supplementation goal was an AA/EPA ratio
between 1.5–3. The investigation of AA/EPA ratios was performed in cases at enrollment (T0), and
repeated after 3 (T3), 6 (T6), and 12 months (T12).
Cholecalciferol supplementation was fixed at 1000 IU/day (25 mcg/day), both in patients receiving
supplementation and controls [21]. Vitamin D was determined as 25(OH)D level in patients receiving
supplementation and controls at the clinical onset of T1D and at enrolment (T0). For patients receiving
supplementation this continued at T3 and T12.
2.2. Diet
At T1D clinical onset, a dietician provided a training courseon the Mediterranean diet [23].
The educational items were standardized [24] (see Supplementary Materials S1). A dietitian’s
counseling was provided to each patient and accompanying parent every 3 months in order to
sustain a Mediterranean diet over time. At T0, written materials were provided on the foods’ main
source of PUFA, to sustain the intake ofω-3-rich foods (blue fish, nuts, walnuts, poultry, eggs, olive oil,
flax seeds, and leafy vegetables) and limit food rich inω-6 (beef, pork, and offal).
At T0 and T12, dietary intakes were assessed based on a weekly food diary and further interviews
to determine macro and micronutrients intake as precisely as possible. The amounts of the nutrients
have been evaluated with the support of the Food Composition Database for Epidemiological
Studies (BDA version 1-2015) [23], assessing protein (g/day), energy (Kcal/day), cholesterol (mg/day),
carbohydrates (g/day), dietary fiber (g/day), vitamin D (g/day), PUFA (g/day), arachidonic acid
(AA g/day), EPA (g/day), and DHA (g/day).
2.3. Assays
Plasma glucose levels (mg/dl; 1 mg/dl:0.05551 mmol/liter) were measured by the gluco-oxidase
colorimetric method (GLUCOFIX®, by Menarini Diagnostics, Florence, Italy). HbA1c% levels were
measured through high-performance liquid chromatography (HPLC), using a Variant machine
(Biorad, Hercules, CA) Intra- and inter-assay coefficients of variation were, respectively, lower
than 0.6% and 1.6%. Linearity was excellent, from 3.2% (11 mmol/mol) to 18.3% (177 mmol/mol).
The presence and titration of antibodies GAD65, IA2 and IAA, expressed in IU/mL, was carried out
by immunoradiometric assay (IRMA), with analytical coefficients of analysis of 13%, 8.4%, and 13%,
respectively. The semi-quantitative determination of TGA, AGAD-G, and AGAD-A, expressed in
IU/mL, was carried out on serum by QUANTA Flash, a rapid response immunochemiluminescence
test (CIA) performed on the BIO-FLASH instrument. The coefficients of analytical variability were,
respectively, 5.5%, 6.7%, and 4.3%. The quantitative determination of the anti-TG and anti-TPO
autoantibodies, expressed in IU/mL, of the TSH, expressed in µUI/mL, and of the fT4, expressed
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in ng/dl, was performed by a competitive immunoassay using a direct immunochemiluminescence
technique, using the Siemens ADVIA centaur XPT system.
The circulating vitamin D levels were measured by serum 25(OH)D assay, using
an immunochemiluminescence (CLIA) method (DiaSorin Liaison Test®, Stillwater, MN, USA).
The coefficient of inter-individual variability of the method (CVa%) was 10%.
Fatty acids (AA, EPA, DHA percentages, and respective AA/EPA ratio) were determined by
high-resolution capillary gas chromatography in whole blood, using dried blood spots testing [25].
The levels of circulating C-peptide, expressed in ng/mL, were measured, on citrate or
heparinized plasma, both by chemiluminescent “sandwich” immunoassay (DiaSorin Liaison®)
and by immunochemiluminescence with the automatic analyzer Immulite 2000 medical system,
with a coefficient of variability of 7.4%.
To asses REIS, we used a composite index of insulin demand adjusted for metabolic control
IDAA1c (calculated asinsulin dose (UI/kg/24 h) × 4 + HbA1c%). A score of <9 met the definition of
partial remission and REIS, according to the previous studies in TrialNet [26].
Tests of HbA1c% were performed every three months, and data on glucometer and, if assigned,
continuous glucose monitoring (CGM), were discharged.
2.4. Statistical Analysis
Data were expressed as mean ± SD of absolute values. The differences between groups were
evaluated for the continuous variables through Mann-Whitney U tests. Chi-square tests were used
to compare the nominal variables between groups. In supplemented subjects, the evaluation of
variation between T0 and T12 for all metabolic parameters was performed with t-test for repeated
measures. The association between the variables was evaluated according to a Pearson test, after
proper logarithmic transformation of the parameters, if required. Trend evaluation across 25(OH)D
levels was performed at the onset though multinomial regression analyses. Moreover, in supplemented
cases, a trend evaluation of metabolic parameters across each time point and timing of supplementation
(T0→ T12) was performed though multinomial regression analyses. Significant p-values were less
than 0.05. All statistical analyses were performed using SPSS 22.0 (SPSS Inc., Chicago, IL, USA).
2.5. Patients
At T0, we analyzed 64 patients (26 supplemented cases and 38 controls, Table 1), then the analysis
during the time of the trial was carried out on 59 patients, whose observations (HbA1c%, average
daily insulin needs (IU/Kg/day) and IDAA1c) were available from recruitment (T0), to 3, 6 and 12
(T12) months. Two cases were dropped because they were not adhering to therapy, two cases stopped
because of ω-3 side effects, and one control was dropped because he changed residence. Finally,
59 patients were evaluated, 22 as supplemented cases and 37 as controls. Only the supplemented cases
receivedω-3 supplementation, as mentioned above.
Table 1. Characteristics of participants at baseline. Data presented as mean + SD or percentages
as appropriate.
Cases Controls p Value
n 26 38
Gender (female/male) 14/12 20/17
Age (years) 8.7 ± 4.6 8.8 ± 3.6 NS
Body weight (Kg) 30.7 ± 17.5 32 ± 14 NS
BMI (Kg/m2) −0.92 ± 1.1 −1.1 ± 2 NS
HbA1c% 11.3 ± 2.2 11.6 ± 2.6 NS
Insulin dose (UI/Kg/day) 0.61 ± 0.22 0.69 ± 0.28 NS
CSII/MDI device 2/24 11/27
BMI (Body Mass Index), HbA1c% (glicosylated Hemoglobin in percentage), CSII (Continuous Subcutaneous Insulin
Injection), MDI (Multiple Daily Injections).
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3. Results
At onset of T1D:Between the whole series (64) of T1D children, we found in 82.5% of cases a vitamin
D insufficiency [≤30 ng/mL (≤75 nmol/L)] in T1D children at time of clinical onset of T1D. A severe
deficiency ≤ 10 ng/mL (25 nmol/L) was present in 12.7%, and those ones displayed a significantly lower
FCP level (p < 0.02) and pH (p < 0.02) than the others. Variability in pH (p < 0.01) and FCP (p < 0.02)
across vitamin D levels was observed.
Patients supplemented vs. not supplemented: At 12 months of ω-3 supplementation (T12),
the cases (n = 22) showed significantly lower insulin needs than the controls (n = 37). In particular,
lower daily insulin needs (0.49± 0.24 vs. 0.63± 0.19 IU/Kg/day; p< 0.01) and pre-meal bolus (0.22 ± 0.16
vs. 0.34 ± 0.14 IU/Kg/day: p < 0.01) were found, without differences in HbA1c% (NS). Analysis of the
IDAA1c index at T12 showed IDAA1c < 9, consistent with a partial remission, in 12 of 22 (54.5%) cases
vs. 7 of 37 controls (18%; p < 0.01) (Figure 1, Tables 2 and 3).
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Table 2. Metabolic parameters and insulin requirements in omega-3 supplemented cases, at enrolment
(T0), and after three (T3), six (T6), twelve (T12) months of supplementation. Data are expressed as mean
± SD. The significance among the four measures (T0, T3, T6, and T12) or three measures (T0, T3, T12)
was calculated by a Friedman test.
T0 T3 T6 T12 pfor trend
Insulin (IU/Kg/day) 0.34 ± 0.2 a 0.37 ± 0.3 0.44 ± 0.2 0.53 ± 0.2 a p < 0.0001
Insulin bolus (IU/Kg/day) 0.15 ± 0.1 c 0.17 ± 0.1 0.20 ± 0.1 0.25 ± 0.1 c p < 0.05
Insulin basal (IU/Kg/day) 0.18 ± 0.1 a 0.20 ± 0.1 0.24 ± 0.1 0.29 ± 0.1 a p < 0.0001
HbA1c (%) 7.7 ± 1.5 7.3 ± 1.1 7.4 ± 1.1 7.4 ± 1 NS
C-peptide (ng/mL) 0.9 ± 0.7 b 0.5 ± 0.3 - 0.38 ± 0.5 b p < 0.01
Mean Glucose (mg/dl) 140 ± 26 155 ± 48 148 ± 38 141 ± 34 NS
DS 50 ± 18 45 ± 24 50 ± 24 57 ± 25 NS
Vitamin D (nmol/L) 31 ± 12 c 41 ± 14 - 35 ± 12 c p < 0.001
AA/EPA 55 ± 38 b 6.8 ± 5 - 8.8 ± 6 b p < 0.0001
a = p < 0.0001 T0 vs. T12; b = p < 0.001 T0 vs. T12; c = p < 0.01 T0 vs. T12. HbA1c% (glicosilated hemoglobin
percentage), AA/EPA (Arachidonic Acid and Eicosapentenoic Acid ratio).
Table 3. Metabolic parameters and insulin requirements in cases supplemented with omega-3
fatty acids (ω-3) vs. not-supplemented patients, after 3 (T3), 6 (T6), and 12 (T12) months of
omega-3 supplementation.
Timing pValue
T3 n S n NS
Insulin (IU/Kg/day)
22
0.37 ± 0.3
37
0.41 ± 0.2 NS
Insulin bolus (IU/Kg/day) 0.17 ± 0.1 0.22 ± 0.1 NS
Insulin basal (IU/Kg/day) 0.20 ± 0.1 0.19 ± 0.1 NS
HbA1c (%) 7.3 ± 1.1 7.6 ± 0.1 NS
IDAA1c < 9 (%) 50% 53% NS
T6 n S n NS
Insulin (IU/Kg/day)
22
0.44 ± 0.2
37
0.51 ± 0.2 NS
Insulin bolus (IU/Kg/day) 0.20 ± 0.1 0.27 ± 0.1 0.06
Insulin basal (IU/Kg/day) 0.24 ± 0.1 0.23 ± 0.1 NS
HbA1c (%) 7.4 ± 1.1 7.5 ± 1.1 NS
IDAA1c < 9 50% 34,1% NS
T12 n S n NS
Insulin (IU/Kg/day) 22 0.49 ± 0.2 37 0.63 ± 0.1 <0.01
Insulin bolus (IU/Kg/day) 0.22 ± 0.1 0.34 ± 0.1 <0.01
Insulin basal (IU/Kg/day) 0.29 ± 0.1 0.28 ± 0.09 NS
HbA1c (%) 7.4 ± 1 7.8 ± 1.0 NS
IDAA1c < 9 54.5% 18.9% <0.01
Data are expressed as mean ± SD. Glicosilated hemoglobin percentage (HbA1c%), Insulin Dose Adjusted for
glicosilated hemoglobin percentage partial remission index (IDAA1c ≤ 9).
The Impact of the Diet
The evaluation of diet composition was made only in cases receiving theω-3 supplementation,
comparing diet intakes at T0 and T12. It showed that within macronutrients, carbohydrate (p < 0.09),
fiber (p < 0.05), and protein (p < 0.05) intakes were lower at T12 then T0. The micronutrients in the diet
were similar for vitamin D, EPA, and DHA (NS). However, the diet intake of AA was significantly
lower (0.25 ± 0.1 vs. 0.20 ± 0.1 g/die; p < 0.01) at T12 vs. T0. The caloric intake was similar at the
beginning and at the end of the one-yearω-3 administration (NS) (Table 4).
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Table 4. Diet composition of supplemented cases at enrollment and after 12 months of ω-3
supplementation. Eicosapentanoic acid (EPA), docosahexaenoic acid (DHA), arachidonic acid (AA),
polyunsaturated fatty acids (PUFAs), carbohydrates (CHO), fibers, and proteins are expressed in
g/day. Vitamin D intake is expressed in µg/day. Data are presented as mean, standard deviation (DS),
and statistical significance (p).
Diet Intake T0 T12 p
Caloric intake (Kcal/day) 1739 ± 556 1576 ± 463 0.09
Protein g/day 73 ± 21 61.4 ± 20 <0.05
Lipid g/day 66 ± 16 64 ± 18 NS
CHO g/day 221 ± 87 190 ± 73 0.09
Fiber g/day 18 ± 7.3 14 ± 4.6 <0.05
Vitamin D µg/day 4 ± 2.7 4.6 ± 1.9 NS
PUFAs g/day 8.6 ± 3.9 10.8 ± 6.5 NS
AA g/day 0.25 ± 0.1 0.20 ± 0.1 <0.01
EPA g/day 0.22 ± 0.1 0.22 ± 0.1 NS
DHA g/day 0.35 ± 25 0.43 ± 0.22 NS
Correlations: At disease onset, 25(OH)D levels were correlated with pH (r: 0.359, p< 0.01). HbA1c%
values were correlated with insulin daily requirement (r: 0.568, p < 0.0001) and weakly inversely
correlated with pH (r: −0.245, p = 0.05). The AA intake at starting point ofω-3 supplementation (T0)
was inversely correlated with HbA1c% (p < 0.05, r: −0.411). After 12 months ofω-3 supplementation,
vitamin D was inversely correlated with HbA1c% (p < 0.05, r: −0.462).
Limitations: There are several limitations to conclude on the efficacy of ω-3 in T1D children.
(1) The study was not randomized; it is therefore a preliminary study to be finalized by subsequent RCTs.
(2) The IDAA1c index is a surrogate of REIS and not a direct evaluation of insulin secretion. (3) Controls
are retrospective, so the comparability of series (Table 2) concerns only some data, such as HbA1c%,
insulin needs, and IDAA1c, but not FCP, AA/EPA, and nutritional intakes. (4) The target AA/EPA levels
weren’t reached with the doses assigned (Table 2).
Side effects: One female child reported diarrhea, so she stopped the fish oil supplement with
a quick return to normality. A female teenager with preexisting thyroiditis presented a transient
suppression of TSH, which returned to normal values three months afterω-3 suspension. One male
child at T12 showed a lengthening of clotting time (aPTT), but the parameters returned gradually to
the norm after suspension of ω-3 supplement without clinical signs of hemorrhage. No other side
effects have been reported, no hemorrhagic clinical symptoms or manifestations that could lead one to
suspect coagulation involvement.
4. Discussion
In the management of T1D, there is a general agreement that the Mediterranean diet improves
metabolic control [27], and the administration of vitamin D supplements avoids its deficiency [4].
A recent systematic review of vitamin D supplementation at the onset of T1D concluded that
alphacalcidole and cholecalciferol supplementations have beneficial effects on daily insulin doses,
HbA1c%, FCP, and SCP. In addition, it indicates that further randomized controlled trials based on
biomarkers are needed to define their optimal contributions [28]. However, there are no directions to
date on supplementation ofω-3 in young T1D subjects, despite some recent anecdotal data showing
persistent partial remissions resulting from vitamin D andω-3 co-supplementation introduced early
after the disease onset [15–17]. Beyond these anecdotal cases, there is little scientific work on clinical
outcomes of co-supplementation of vitamin D andω-3 in recent-onset T1D. In this study involving
a series of T1D children, already assuming a Mediterranean diet and cholecalciferol, the additional
supplement ofω-3 in recent-onset cases seemed to have beneficial effects, which suggests the need to
design further RCTs.
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Our previous findings in this context showed a widespread insufficiency of vitamin D at the
clinical onset of T1D and a relationship between its severe deficiency with reduced FCP and pH at
clinical onset, in line with the reports of other authors [29–31]. This highlights the importance of vitamin
D status in childhood to determine the severity of T1D at clinical onset. Ultimately, it is mandatory to
correct vitamin D deficiency from the onset of T1D.
In our study, the daily supplementation of ω-3 starting from clinical onset led to, one year
later, less insulin demand without affecting glycemic control, since the subjects had similar HbA1c%.
Considering IDAA1c (insulin dose adjusted for HbA1c%) as a surrogate index of residual β-cell
function, and IDAA1c ≤ 9 is indicative of partial remission of T1D [25], our data show that ω-3
may preserve β-cell secretion. This finding, if confirmed by further RCTs, might be considered for
assisting children beginning at the onset of the disease. The clinical outcome of a reduced insulin
demand, mainly at meals, is compatible with the hypothesis of the inhibition of postprandial protein
neoglucogenesis [10]. Interestingly, the effects of co-supplementation of vitamin D andω-3 have also
been reported in randomized clinical trials outside of childhood T1D, on gestational diabetes and on
multiple sclerosis [32,33]. Those studies reported a reduction of blood glucose and fasting plasma
insulin, and an increase of insulin sensitivity. Particularly, the trial on gestational diabetes highlighted
a synergism of vitamin D and ω-3 [33]. While clinical randomized trials on co-supplementation of
vitamin D and ω-3 in T1D are ongoing, our data suggest a benefit, and aim at finalizing further
randomized investigations to the topic.
Despite the apparent benefits of reduced insulin demand in those who tookω-3 supplements, in our
study, we found similar HbA1c% at comparable points from the onset of disease for both supplemented
cases and controls, which represents a similar outcome to metabolic balance. This likely occurred
with the addition of insulin doses in controls to keep their blood sugar within limits. Unexpectedly,
we found a decreasing trend of fasting C-peptide (FCP) from the start ofω-3 supplement (T0) to one
year later (T12). A plausible explanation for similar metabolic control with less insulin administration,
despite decreased FCP, is probably related to the counteraction ofω-3 on neoglucogenesis, which limits
postprandial glucose increase and reduces insulin need for meals. The lowering of the blood glucose
excursions could in turn affect the process of apoptosis of β-cells reducing glucolipotoxicity, and so
could preserve REIS, according to findings in translational models [11]. This assumption might be
investigated through analysis of stimulated C-peptide (SCP) after a standardized mixed-meal tolerance
test, which allows for a direct measurement of insulin secretion, in future RCTs. A possible immune
regulatory role ofω-3 supplementation could concur, together with vitamin D, to improve T1D, and
should be investigated by assessing biomarkers of autoimmunity (e.g., lymphocyte subpopulations
Treg or Th-17). This study could not determine if the decreased insulin demand is sustained only by
reduced needs or also by preserved REIS over time, because IDAA1c is a composite index of insulin
needs and metabolic control, but not a direct measurement of REIS.
Another limit of this study is the failure to achieve the target levels of the AA/EPA ratio, probably
due to reduced compliance of pediatric patients in the assumption of fish oil, or insufficient dosage.
Reaching an AA/EPA range 1.5–3 will therefore be a goal in future trials.
The diet analysis in theω-3 supplemented group, showed a decrease of carbohydrates, from T0 to
T12, which although not significant, may have played part to the reduction of pre-prandial insulin
demands. Protein and fiber moderately decreased, and no significant changes were found in terms of
total lipids. EPA and DHA in the diet were unmodified and not significantly increased, respectively.
The reduction of AA intake was significant and relevant. It is likely that the AA reduction takes part in
determining decrease of AA/EPA and outcomes. This might be related to a competition betweenω-3
and ω-6 for the common metabolic pathway of LCFA and suggests that a reduction of AA nutritional
intake could improve the results of omega 3 supplementation and it should undergo future research in
further studies.
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5. Conclusions
Given that this study is a preliminary to future RCTs, our findings suggest that aω-3 supplement,
in the context of a Mediterranean diet and vitamin D administration, gives benefits to children with
T1D, with a reduction of insulin requirements after 12 months of supplementation, despite a decrease
in FCP. Vitamin D and dietary intake ofω-3 and AA play a role in whether metabolic control becomes
better or worse, and perhaps whether favorable or unfavorable autoimmunity follows. Particularly,
further investigations should consider the direct biomarkers of insulin secretion (such as SCP) and of
T-cell immune-regulatory subgroups (such as Tregs, Th17), to define if AA andω-3 assign metabolic or
immune effects, or both.
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